证券代码：002020 证券简称：京新药业 公告编号：2020044 浙江京新药业股份有限公司 关于参加浙江辖区上市公司投资者网上集 体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的沟通交流，浙江京新药业股份有限公司（以下简称 "公司"）将参加由浙江证监局指导、浙江上市公司协会与深圳市全景网络有限 公司共同举办的"凝心聚力 共克时艰"辖区上市公司投资者网上集体接待日活 动，现将有关事项公告如下： 本次投资者网上集体接待日活动将通过深圳市全景网络有限公司提供的网 上平台举行，投资者可以登录"全景.路演天下"网站（http://rs.p5w.net）参 与公司本次投资者网上接待日活动。网上互动交流时间为 2020 年 5 月 15 日 星期五）15:00-17:00。 届时公司副总裁兼财务总监陈美丽女士、董事会秘书洪贇飞先生将采用网络 远程方式与投资者就公司治理、发展战略、经营状况、可持续发展等问题进行沟 通（如有特殊情况，参与人员会有调整）。 欢迎广大投资者积极参与。 特此公告。 浙江京新药业股份有限公司董事会 二 O ...

Financial Performance - The company's operating revenue for Q1 2020 was ¥793,742,204.43, a decrease of 11.15% compared to ¥893,372,399.42 in the same period last year[9] - Net profit attributable to shareholders was ¥95,666,199.21, down 27.18% from ¥131,379,249.16 year-on-year[9] - The net profit after deducting non-recurring gains and losses was ¥79,533,640.22, a decrease of 15.60% compared to ¥94,231,955.93 in the previous year[9] - Basic and diluted earnings per share were both ¥0.1329, down 29.87% from ¥0.1895 in the previous year[9] - Total revenue for the current period is ¥793,742,204.43, a decrease of 11.2% compared to ¥893,372,399.42 in the previous period[76] - Net profit for the current period is ¥96,502,982.74, a decrease of 26.7% from ¥131,530,009.98 in the previous period[83] - Operating profit decreased to ¥76,490,200.26, down 34.7% from ¥117,331,987.97 in the previous period[87] - Total comprehensive income for the current period is ¥69,585,952.89, compared to ¥105,784,721.57 in the previous period[90] Cash Flow - The net cash flow from operating activities increased by 76.02% to ¥121,862,146.77 from ¥69,232,593.75 in the same period last year[9] - Cash flow from operating activities generated a net amount of ¥121,862,146.77, an increase of 76.2% from ¥69,232,593.75 in the previous period[91] - Net cash flow from financing activities increased by 3762.44% to ¥227,635,340.82, primarily due to an increase in cash received from borrowings[40] - Financing activities generated a net cash inflow of ¥227,635,340.82, compared to a net outflow of ¥6,215,408.54 in the previous period[97] - Investment activities resulted in a net cash outflow of ¥278,056,622.69, worsening from a net outflow of ¥100,485,380.69 in the previous period[94] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,841,770,264.99, an increase of 3.85% from ¥5,625,088,046.03 at the end of the previous year[9] - Total liabilities increased to CNY 2,105,001,046.32 from CNY 1,914,376,310.28, representing a growth of about 9.93%[64] - Total current liabilities amounted to CNY 1,961,932,464.72, an increase from CNY 1,770,292,227.81, reflecting a growth of about 10.80%[64] - Total assets amounted to CNY 4,862,688,352.78, with current assets at CNY 2,544,359,556.59 and non-current assets at CNY 2,318,328,796.19[111] Shareholder Equity - Net assets attributable to shareholders were ¥3,722,181,288.11, a slight increase of 0.71% from ¥3,696,079,802.35 at the end of the previous year[9] - The company's equity attributable to shareholders reached CNY 3,722,181,288.11, up from CNY 3,696,079,802.35, an increase of approximately 0.71%[67] - The company has a total of CNY 3,710,711,735.75 in total equity, including minority interests of CNY 14,631,933.40[108] Expenses - Total operating costs for the current period are ¥707,217,154.49, down 8.7% from ¥774,883,655.75 in the previous period[79] - Research and development expenses for the current period are ¥66,227,053.39, an increase from ¥51,043,288.08 in the previous period[79] - The company reported a decrease in sales expenses to ¥159,789,393.41, down 1.1% from ¥161,588,371.99 in the previous period[87] Other Financial Metrics - The weighted average return on equity decreased by 1.04 percentage points to 2.63% from 3.67% in the previous year[9] - The company reported a non-operating income of ¥16,132,558.99 during the reporting period[9] - Other income increased by 144.26% to ¥14,124,151.09, primarily due to an increase in government subsidies[31] - The company received 200,000,000.00 CNY in loans during the financing activities, indicating a reliance on debt financing[101] Miscellaneous - The company established a wholly-owned subsidiary in Shandong Province with an investment of ¥12,000,000 to promote the orderly implementation of the Weifang project[42] - The first quarter report for 2020 was not audited[114]

Financial Performance - The company's operating revenue for 2019 was CNY 3,646,683,905.76, representing a 23.88% increase compared to CNY 2,943,801,995.73 in 2018[21] - The net profit attributable to shareholders of the listed company reached CNY 520,396,181.46, a 40.92% increase from CNY 370,036,653.03 in the previous year[21] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 421,098,548.74, up 33.53% from CNY 316,121,885.58 in 2018[21] - The basic earnings per share increased to CNY 0.729, reflecting a growth of 42.66% from CNY 0.512 in the previous year[21] - The net cash flow from operating activities was CNY 535,301,257.28, showing a slight increase of 2.36% compared to CNY 523,403,340.87 in 2018[21] - Total assets increased by 12.10% year-over-year, reaching CNY 5,625,088,046.03 at the end of 2019[25] - The return on equity (ROE) was 14.41%, an increase of 4.64 percentage points from the previous year[56] - The gross profit margin for the main business was 65.03%, with a year-on-year increase of 0.34%[69] Dividends and Shareholder Returns - The company plans to distribute a cash dividend of CNY 3.50 per 10 shares (including tax) to all shareholders[5] - The total cash dividends distributed in 2019 accounted for 45.18% of the net profit attributable to ordinary shareholders, which was 520,396,181.46 RMB[137] - The cash dividend distribution policy is based on the total share capital on the record date, excluding repurchased shares[132] - The cash dividends for the last three years have shown a consistent increase, reflecting the company's commitment to returning value to shareholders[137] Business Operations and Strategy - The company continues to focus on the research and development of chemical preparations, traditional Chinese medicine, and medical devices[36] - The company aims to strengthen its pharmaceutical business while expanding into the medical device sector[40] - The company is recognized as a leading enterprise in the internationalization of Chinese pharmaceutical formulations[40] - The company has maintained a strong growth trajectory despite the overall slowdown in the pharmaceutical industry[39] - The company has established a complete pharmaceutical industry chain, enhancing cost advantages and market competitiveness[46] - The company has expanded its marketing network across commercial channels, retail pharmacies, and clinical hospitals, enhancing brand recognition and influence[52] Research and Development - The company has a total of 142 valid patents, including 94 domestic invention patents and 3 US invention patents, reflecting strong R&D capabilities[47][48] - The company has made significant progress in its R&D pipeline, with five products in the psychiatric and neurological field and three in the cardiovascular field currently under development[62] - The company has submitted registration applications for seven generic drug products, with four products already approved, including Rosuvastatin calcium dispersible tablets and Levetiracetam oral solution[63] Market Performance - Sales in the cardiovascular product category amounted to ¥1.11 billion, while sales in the psychiatric and neurological products reached ¥272 million, and gastrointestinal products totaled ¥417 million, indicating a continuous increase in market share across these therapeutic areas[57] - The company achieved over 50% market share in the domestic medical imaging display terminal market, with more than 8,000 terminal hospital users[61] Financial Management - The company reported a total of CNY 4,981.14 million invested in the annual production expansion project of solid preparations during the reporting period[94] - The company has committed to a total investment of CNY 15,071.02 million for the traditional Chinese medicine comprehensive preparation technology transformation project, with only CNY 620.75 million invested to date, indicating a progress of 4.12%[94] - The company has not made any significant equity investments during the reporting period[91] - The company has not changed the purpose of the raised funds during the reporting period, maintaining the original investment commitments[93] Compliance and Governance - The company has committed to strict compliance with regulations regarding the transfer of shares and related party transactions[142] - The company has ensured that all related transactions comply with legal regulations and are conducted at fair market prices[142] - The company has not faced any major litigation or arbitration matters during the reporting period[160] Environmental Responsibility - The company has established a comprehensive environmental management system, certified by ISO14001, to ensure pollution control and compliance with national regulations[188] - The total discharge of COD from the company's facilities was 128.79 tons, which is below the approved limit of 263.28 tons, indicating no exceedance of discharge standards[193] - The company has invested in a wastewater treatment system with a daily capacity of 2400 tons, ensuring that all wastewater meets discharge standards[194] Employee Engagement and Welfare - The company has implemented a talent development system, including training programs and employee engagement initiatives[185] - The company emphasizes employee rights protection and has established a comprehensive internal control system to ensure fair treatment of all shareholders[182] - The company engaged in related party transactions, with a total transaction amount of 3,500,000 yuan for packaging materials, representing 35.65% of the same type of transactions[167]

Group 1: Event Details - Zhejiang Jingxin Pharmaceutical Co., Ltd. will participate in the "Communication Promotes Development, Rational Growth Together" online investor reception day event [2] - The event is guided by the Zhejiang Securities Regulatory Bureau and organized by the Zhejiang Listed Companies Association and Shenzhen Panorama Network Co., Ltd. [2] - The online interaction will take place on November 5, 2019, from 15:30 to 17:00 [2] Group 2: Participation and Communication - Company President and Board Secretary Jin Zhiping and Vice President and CFO Chen Meili will communicate with investors via remote online methods [2] - Investors are encouraged to actively participate in the event [2] Group 3: Assurance of Information Disclosure - The company and its board members guarantee the authenticity, accuracy, and completeness of the disclosed information, with no false records, misleading statements, or significant omissions [2]

Financial Performance - Operating revenue for the period reached CNY 936,980,485.80, representing a year-on-year growth of 13.77%[9] - Net profit attributable to shareholders increased by 27.56% to CNY 163,197,581.01 for the quarter[9] - The total profit for the period was CNY 568.52 million, an increase of 44.89% compared to the same period last year, mainly due to growth in main business income[31] - Net profit for the period was CNY 489.44 million, an increase of 43.98% compared to the same period last year, primarily due to the increase in total profit[31] - Investment income for the period was CNY 94.89 million, an increase of 76.90% compared to the same period last year, mainly due to increased financial investment returns[30] - Other income for the period was CNY 21.28 million, an increase of 44.63% compared to the same period last year, primarily due to government subsidies[28] - The total profit for the current period was ¥579,370,073.35, up from ¥326,551,792.28 in the previous period, representing an increase of approximately 77.2%[84] - Net profit attributable to the parent company was ¥488,972,456.62, compared to ¥341,006,983.04 in the same period last year, reflecting a year-on-year increase of about 43.5%[81] Earnings and Shareholder Information - Basic earnings per share increased by 41.18% to CNY 0.24[9] - The company reported a total of 35,496 shareholders at the end of the reporting period[13] - The top shareholder, Lü Gang, holds 20.55% of the shares, totaling 148,997,296 shares[14] - Basic and diluted earnings per share for the current period were both ¥0.24, up from ¥0.17 in the previous period[71] - Earnings per share (basic and diluted) for the current period were both ¥0.71, up from ¥0.47 in the same period last year, reflecting a growth of approximately 51.1%[81] Assets and Liabilities - Total assets increased by 9.11% to CNY 5,446,582,277.25 compared to the end of the previous year[9] - Current liabilities increased to CNY 1,638,363,139.53 from CNY 1,341,005,665.56 year-on-year[52] - Total liabilities amounted to CNY 1,713,612,688.60, up from CNY 1,418,374,285.05[52] - Total assets reached CNY 5,446,582,277.25, an increase from CNY 4,991,769,097.50[49] - The company reported a total non-current asset value of CNY 1,956,235,985.88[112] - The total liabilities increased to ¥1,293,304,523.01 from ¥1,028,301,308.22, representing a rise of 25.8%[62] Cash Flow - Cash flow from operating activities showed a net increase of 12.52% to CNY 101,326,127.88[9] - Operating cash inflow for the current period reached ¥3,184,155,740.14, a 25.3% increase from ¥2,542,091,730.54 in the previous period[88] - Net cash flow from operating activities was ¥415,879,809.68, up 64.5% from ¥252,623,991.90 year-on-year[91] - Cash inflow from investment activities totaled ¥2,242,089,867.94, a decrease of 6.3% compared to ¥2,392,186,517.17 in the previous period[91] - Cash outflow from financing activities was ¥360,935,551.82, down 34.7% from ¥553,627,108.89 year-on-year[94] Share Repurchase and Equity - The company did not engage in any repurchase agreements during the reporting period[17] - The company repurchased a total of 38.25 million shares, accounting for 5.28% of the total share capital, with a total payment of CNY 378.17 million[36] - The company’s undistributed profits at the end of the period were CNY 1.13 billion, an increase of 33.58% compared to the beginning of the year, mainly due to increased profits[26] Research and Development - Research and development expenses increased to ¥81,247,157.55, compared to ¥64,144,055.32, marking a growth of 26.7%[65] - Research and development expenses increased to ¥31,620,000, up from ¥27,535,108, reflecting a growth of 14.5%[72] - Research and development expenses amounted to ¥81,762,166.37, slightly higher than ¥79,938,913.39 in the previous period, showing an increase of about 2.3%[84] Market Strategy - The company plans to continue expanding its market presence and investing in new product development to drive future growth[65]

Financial Performance - The company's operating revenue for the first half of 2019 was CNY 1,858,537,759.35, representing a 31.92% increase compared to CNY 1,408,821,727.66 in the same period last year[21] - The net profit attributable to shareholders of the listed company reached CNY 325,774,875.61, up 52.89% from CNY 213,071,117.43 year-on-year[21] - The net cash flow from operating activities was CNY 314,553,681.80, a significant increase of 93.49% compared to CNY 162,569,976.41 in the previous year[21] - Basic earnings per share increased to CNY 0.472, reflecting a growth of 61.64% from CNY 0.292 in the same period last year[21] - The gross profit margin for the main business was 63.13%, an increase of 0.37 percentage points year-on-year, while the net profit margin was 17.53%, up by 2.4 percentage points[53] - The finished drug business generated sales revenue of RMB 1.09 billion, a 32% increase year-on-year, with key products like the statin series showing significant growth[53] - The raw material drug segment reported sales of RMB 536 million, up 33% year-on-year, with specialty raw materials growing by 71%[54] - The company expects a net profit for the first three quarters of 2019 to increase by 40% to 50%, with an estimated range of RMB 477.4 million to RMB 511.5 million[100] Assets and Liabilities - The total assets at the end of the reporting period were CNY 5,280,198,677.22, which is a 5.78% increase from CNY 4,991,769,097.50 at the end of the previous year[21] - The company's total liabilities rose to CNY 1,691,979,668.95 from CNY 1,418,374,285.05, marking an increase of around 19.2%[197] - The equity attributable to the owners of the parent company increased to CNY 3,576,051,487.15 from CNY 3,561,772,412.70, showing a slight growth of about 0.4%[196] - The company's current assets totaled CNY 3,297,416,560.87 as of June 30, 2019, compared to CNY 3,035,533,111.62 at the end of 2018, indicating an increase of about 8.7%[191] - The inventory as of June 30, 2019, was CNY 376,565,501.54, up from CNY 362,550,740.79, which is an increase of approximately 3.9%[191] - The accounts receivable increased to CNY 461,936,713.72 from CNY 429,837,662.92, representing a growth of about 7.5%[188] - The short-term borrowings significantly increased to CNY 360,793,776.04 from CNY 150,000,000.00, indicating a rise of approximately 140.5%[192] Investment and R&D - R&D investment reached RMB 140 million, a 10.41% increase year-on-year, focusing on the development of new drugs and innovative products[57] - The company has a rich product structure with over 20 generic drug projects, 10 modified innovative drug/device projects, and 4 innovative drugs in development, covering cardiovascular, digestive, and mental health fields[40] - The company holds a total of 111 effective patents, including 85 domestic invention patents and 3 US invention patents, reflecting strong R&D capabilities[42] - The company submitted registration applications for six generic drugs during the reporting period, including new formulations of existing products[57] Corporate Governance and Shareholder Information - The company plans not to distribute cash dividends or issue bonus shares during this reporting period[5] - The company held its annual general meeting on May 17, 2019, with a participation rate of 31.03%[105] - The company completed the lock-up period for shares acquired during the asset restructuring, with a 36-month lock-up period divided into three phases: 30% after 12 months, 30% after 24 months, and 40% after 36 months[106] - The largest shareholder, Lü Gang, holds 20.55% of the shares, totaling 148,997,296 shares, with 90,300,000 shares pledged[160] - The company has 24,734 shareholders holding more than 5% of the shares at the end of the reporting period[160] Risk Management and Compliance - The company has outlined potential risks and countermeasures in its operational analysis section, ensuring transparency regarding its risk management strategies[5] - The company is facing risks related to industry policy changes, R&D uncertainties, and talent shortages, and is taking measures to address these challenges[101] - The company has complied with regulations regarding the disclosure of raised funds usage, ensuring accuracy and completeness[91] Environmental Responsibility - The company emphasizes the concept of "Healthy Nation" and adheres to national environmental laws as a fundamental principle[136] - The wastewater treatment system has a daily processing capacity of 2300 tons, ensuring compliance with discharge standards[138] - The company has achieved stable operation of pollution control facilities, with all pollutants meeting discharge standards and no environmental pollution incidents reported[140] - The company conducts regular monitoring of wastewater and air emissions, with automatic online monitoring for key parameters[146][147]

Financial Performance - The company's operating revenue for 2018 was CNY 2,943,801,995.73, representing a 32.66% increase compared to CNY 2,219,065,970.18 in 2017[21] - The net profit attributable to shareholders for 2018 was CNY 370,036,653.03, a 39.97% increase from CNY 264,376,949.76 in 2017[21] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 316,121,885.58, showing a significant increase of 653.97% compared to CNY 41,927,741.31 in 2017[21] - The basic earnings per share for 2018 was CNY 0.512, up 29.95% from CNY 0.394 in 2017[21] - The total assets at the end of 2018 were CNY 4,991,769,097.50, a 1.79% increase from CNY 4,903,994,210.21 at the end of 2017[21] - The net cash flow from operating activities for 2018 was CNY 523,403,340.87, which is a 35.95% increase from CNY 385,007,181.40 in 2017[21] - The weighted average return on net assets for 2018 was 9.79%, an increase from 9.17% in 2017[21] - The gross profit margin for the main business was 64.69%, up by 6.12 percentage points, while the net profit margin reached 12.57%, an increase of 0.66 percentage points[53] - The main business revenue accounted for 98.85% of total revenue, with a year-on-year growth of 33.06%[59] - The pharmaceutical manufacturing segment generated 2.55 billion yuan, which is 86.62% of total revenue, with a 40.31% year-on-year increase[59] Revenue Breakdown - The company's total revenue for the four quarters was as follows: Q1: ¥643.60 million, Q2: ¥765.22 million, Q3: ¥823.58 million, Q4: ¥711.40 million[25] - The net profit attributable to shareholders for the four quarters was: Q1: ¥88.03 million, Q2: ¥125.05 million, Q3: ¥127.94 million, Q4: ¥29.03 million[25] - The finished drug business generated a sales revenue of 1.678 billion yuan, with a year-on-year growth of 46.95%[53] - The sales of traditional quinolone raw materials, including levofloxacin and ciprofloxacin, reached 544 million yuan, up 19% year-on-year[54] - The sales of specialty raw materials, such as simvastatin and escitalopram, amounted to 304 million yuan, reflecting a 60% year-on-year growth[54] - The medical device segment generated sales revenue of 394 million yuan, with ODM business sales contributing 315 million yuan, a 7% increase year-on-year[54] Research and Development - Research and development investment totaled 242 million yuan in 2018, marking a year-on-year increase[54] - The company holds a total of 125 valid patents, including 80 domestic invention patents, showcasing its strong R&D capabilities[44] - The company has a rich product pipeline with nearly 10 products undergoing consistency evaluation and 20 generic drug projects in progress[41] - The company focused on developing new products in therapeutic areas, emphasizing innovative and barrier-protected drugs[72] - The company is focused on improving R&D efficiency and advancing key projects to adapt to innovation transformation[115] Dividend Policy - The company plans to distribute a cash dividend of CNY 3.00 per 10 shares (including tax) to all shareholders[5] - The total cash dividend for 2018, including other methods, reached 473,470,573.09 RMB, representing 100% of the distributable profit[127] - The company's cash dividend payout ratio for 2018 was 55.70% of the net profit attributable to ordinary shareholders[126] - The company has maintained a consistent cash dividend distribution policy over the past three years, with no stock or capital reserve increases[123][124][125] - The company is in a mature development stage and aims to maintain a minimum cash dividend ratio of 40% during profit distribution[127] Business Strategy - The company aims to become a leader in the fields of mental health and cardiovascular medicine in China, focusing on both pharmaceuticals and medical devices[35] - The company has established a complete pharmaceutical industry chain from raw materials to finished products, enhancing its cost advantages and market competitiveness[42] - The marketing network covers commercial channels, retail pharmacies, and clinical hospitals nationwide, enhancing brand recognition and influence[49] - The company plans to strengthen the raw material drug strategy through new product development, market expansion, and cost reduction of existing products[114] Environmental Management - The company has established a comprehensive environmental management system, certified by ISO 14001, to ensure compliance with pollution control standards[179] - The company has a daily wastewater treatment capacity of 2,300 tons, ensuring that treated wastewater meets discharge standards[185] - The company has successfully maintained stable operation of pollution control facilities, with all pollutants meeting discharge standards and no environmental pollution incidents reported[188] - The company has invested in clean production and pollution prevention technologies to support its environmental management strategy[188] - Regular monitoring of wastewater and air emissions is conducted, with results published on relevant environmental information platforms[195][196] Risks and Challenges - The company faces risks from changing industry policies, including the impact of national drug procurement policies and the need for consistent evaluation of generic drugs[118] - The company acknowledges potential R&D risks due to stricter regulations and the inherent uncertainties in new drug development[118] - The company recognizes the risk of talent shortages as it expands and develops, which may affect strategic execution and management[118] Corporate Governance - The company has established a commitment to avoid related party transactions unless absolutely necessary, ensuring fairness and compliance with legal requirements[134] - The company has committed to strict performance of share lock-up agreements for newly issued shares for a period of 36 months[130] - The company has a long-term commitment to comply with all regulatory requirements regarding share transactions and disclosures[130] - The company has a long-term commitment to avoid any direct or indirect competition with its subsidiaries, ensuring that any business opportunities that may conflict will be reported to the company[132]

Financial Performance - The company's operating revenue for Q1 2019 was ¥893,372,399.42, representing a 38.81% increase compared to ¥643,598,548.68 in the same period last year[8] - Net profit attributable to shareholders was ¥131,379,249.16, up 49.25% from ¥88,025,890.09 year-on-year[8] - The net profit after deducting non-recurring gains and losses was ¥94,231,955.93, reflecting a 20.43% increase from ¥78,248,681.20 in the previous year[8] - Basic earnings per share rose to ¥0.1895, a 58.44% increase from ¥0.1196 in the previous year[8] - Operating revenue grew by 38.81% to ¥893,372,399.42, attributed to an increase in main business income[26] - Operating profit rose by 51.58% to ¥153,925,261.90, driven by increased operating revenue and investment income[30] - Net profit for Q1 2019 was ¥131,530,009.98, representing a 52.3% increase compared to ¥86,374,600.57 in Q1 2018[65] - The total profit for the period was ¥158,012,952.26, up 53.4% from ¥103,050,865.10 in Q1 2018[65] Cash Flow - The net cash flow from operating activities was ¥69,232,593.75, an increase of 38.16% compared to ¥50,109,446.25 in the same period last year[8] - Cash inflow from operating activities reached CNY 1,012,255,923.29, an increase of 30.3% compared to CNY 776,385,856.96 in the previous period[74] - Cash inflow from sales of goods and services was CNY 940,219,381.99, up from CNY 716,370,627.79 in the previous period, reflecting a growth of 31.3%[74] - Cash outflow for purchasing goods and services was CNY 399,430,662.60, an increase of 18.4% from CNY 337,461,427.94 in the previous period[78] - The company reported a net cash increase of -CNY 38,695,110.14, compared to an increase of CNY 45,995,303.07 in the previous period[79] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,246,389,385.99, a 5.10% increase from ¥4,991,769,097.50 at the end of the previous year[8] - Current liabilities totaled CNY 1,574,747,620.55, an increase of 17.4% from CNY 1,341,005,665.56 in the previous period[49] - Total liabilities reached CNY 1,650,998,882.87, up 16.4% from CNY 1,418,374,285.05[51] - Total equity attributable to shareholders was CNY 3,583,362,953.31, an increase of 0.6% from CNY 3,561,772,412.70[51] - Total assets as of March 31, 2019, amounted to ¥5,246,389,385.99, an increase from ¥4,991,769,097.50 at the end of 2018[44] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 23,988[12] - The largest shareholder, Lü Gang, holds 20.55% of the shares, with a total of 148,997,296 shares[12] Investment and Income - The company reported non-operating income of ¥8,006,000.72 from government subsidies and ¥36,095,859.42 from entrusted investment management[8] - Investment income surged by 323.38% to ¥36,095,859.42, mainly from gains on the disposal of securities[29] - Other income increased significantly to ¥5,782,340.63 from ¥1,694,478.60, marking a growth of 241.5%[65] Research and Development - Research and development expenses rose to ¥51,043,288.08, a 10.5% increase from ¥46,296,527.46 in the prior year[62]

Financial Performance - Operating revenue for the reporting period was ¥823,582,145.10, representing a year-on-year growth of 50.45%[8] - Net profit attributable to shareholders was ¥127,935,865.61, up 61.77% from the same period last year[8] - Basic earnings per share increased by 42.34% to ¥0.1765[8] - The company's net assets attributable to shareholders decreased by 5.90% to ¥3,689,492,465.64[8] - The weighted average return on equity was 3.52%, an increase of 0.53 percentage points[8] - Revenue for the period was ¥2.23 billion, a 44.40% increase year-on-year, driven by growth in core business income[23] - Net profit attributable to shareholders increased by 35.86% to ¥872.48 million, driven by higher profits for the year[23] - The estimated net profit attributable to shareholders for 2018 is expected to increase by 30.00% to 40.00%, ranging from 343.69 million to 370.12 million CNY[27] - The net profit for 2017 attributable to shareholders was 264.38 million CNY[27] - The company reports stable growth in its main business as the reason for the profit increase[27] Cash Flow and Investments - The net cash flow from operating activities surged by 333.38% to ¥90,054,015.49[8] - The company reported non-recurring gains of ¥50,946,872.24 for the year-to-date[12] - The company reported an investment income of ¥53.64 million, a significant increase of 151.22% year-on-year, mainly from increased financial investment returns[23] - The company has engaged in entrusted financial management with a total amount of 142 million CNY, including 46.5 million CNY from idle raised funds and 88.5 million CNY from idle self-owned funds[31] - The total balance of entrusted financial management that has not matured is 166 million CNY[31] - There are no overdue amounts that have not been recovered from entrusted financial management[31] Shareholder Information - The company repurchased a total of 12,575,260 shares during the reporting period[9] - The company repurchased 12.58 million shares, accounting for 1.73% of total share capital, with a total expenditure of ¥140.37 million[25] - The top shareholder, Lü Gang, holds 20.55% of the shares, with 90,600,000 shares pledged[14] - The chairman of the company is Lü Gang[32] Assets and Liabilities - Total assets at the end of the reporting period reached ¥4,989,704,767.25, an increase of 1.75% compared to the end of the previous year[8] - Accounts receivable at the end of the period reached ¥500.28 million, an increase of 36.62% compared to the beginning of the year, primarily due to sales growth[18] - Short-term borrowings increased by ¥150 million, marking a 100% increase, mainly due to an increase in bank discounted notes[19] - Other receivables decreased by 44.69% to ¥125.45 million, primarily due to compensation amounts not being recovered from Shenzhen Juyun Display Technology Co., Ltd.[20] Expenses - Sales expenses rose to ¥757.25 million, an increase of 80.11% year-on-year, attributed to higher business service fees related to revenue growth[23] - R&D expenses amounted to ¥190.52 million, up 41.13% year-on-year, reflecting increased investment in research and development[23] Compliance and Governance - The company has no overdue commitments from controlling shareholders or related parties during the reporting period[26] - There are no violations regarding external guarantees during the reporting period[28] - The company did not conduct any research, communication, or interview activities during the reporting period[29]

Financial Performance - The company's operating revenue for the first half of 2018 was CNY 1,408,821,727.66, representing a 41.08% increase compared to CNY 998,563,934.08 in the same period last year[16]. - The net profit attributable to shareholders of the listed company was CNY 213,071,117.43, up 25.34% from CNY 169,994,950.67 year-on-year[16]. - The net profit after deducting non-recurring gains and losses was CNY 191,828,974.90, an increase of 24.67% compared to CNY 153,870,360.10 in the previous year[16]. - The basic earnings per share increased by 9.02% to CNY 0.290 from CNY 0.266 in the same period last year[16]. - The total comprehensive income for the first half of 2018 was CNY 90,008,716.27, down from CNY 172,857,381.48 in the previous year[153]. - The company reported a significant increase in sales expenses, totaling CNY 455,180,328.91, compared to CNY 242,628,531.63 in the previous year, reflecting a rise of 87.7%[152]. - The company reported a net profit forecast for Q1-Q3 2018, estimating a range of 32,380.32 to 34,871.12 million CNY, representing a year-on-year increase of 30% to 40%[80]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 4,640,723,114.58, a decrease of 5.37% from CNY 4,903,994,210.21 at the end of the previous year[16]. - The net assets attributable to shareholders of the listed company decreased by 8.00% to CNY 3,606,807,459.40 from CNY 3,920,617,698.12 at the end of the previous year[16]. - Total liabilities increased to CNY 993,846,377.37, up 5.9% from CNY 938,430,799.15[144]. - Owner's equity totaled CNY 3,646,876,737.21, down from CNY 3,965,563,411.06, representing a decrease of 8.0%[145]. Cash Flow - The company reported a net cash flow from operating activities of CNY 162,569,976.41, a slight decrease of 2.12% from CNY 166,084,129.47 in the previous year[16]. - The net cash flow from operating activities for the current period is CNY 232,332,090.49, a significant increase from CNY 19,757,160.62 in the previous period, representing a growth of approximately 1,075%[163]. - The total cash inflow from investment activities reached CNY 1,096,457,354.87, compared to CNY 275,715,286.97 in the prior period, indicating a growth of about 297%[163]. - The cash outflow from financing activities totaled CNY 250,352,117.72, compared to CNY 164,089,349.03 in the prior period, marking an increase of about 52.6%[163]. Research and Development - The company has a total of 107 valid patents, including 69 domestic invention patents and 2 US invention patents, reflecting strong R&D capabilities[36]. - Research and development investment increased by 64.09% to CNY 126 million, driven by the expansion of R&D projects[50]. - The company aims to leverage R&D innovation, market expansion, and investment strategies to enhance its core competitiveness and achieve rapid development[29]. Market Position and Products - The company continues to engage in the research, development, production, and sales of chemical preparations, traditional Chinese medicine, biological preparations, chemical raw materials, and medical devices[25]. - The company has achieved a leading market position in the blood lipid regulation field with its main products, including "Jingnuo" (Rosuvastatin Calcium Tablets) and "Jingkexin" (Pitavastatin Calcium Dispersible Tablets) for treating hypercholesterolemia[26]. - The finished drug business generated sales of CNY 823 million, with a year-on-year growth of 62%[45]. - The core products collectively achieved sales exceeding CNY 600 million, with a growth rate of 65%[45]. Investment and Expansion - The company plans to expand its production capacity to 2 billion solid preparations by the end of 2019, with an investment of 35,949.3 million CNY allocated for this project[68]. - The company has ongoing investments in SEPS Pharma Limited and Vascular Graft Solutions Ltd, totaling ¥34,299,720.00[60]. - The company is actively pursuing new product development and market expansion strategies to enhance its competitive position in the pharmaceutical industry[68]. Compliance and Governance - The financial report for the first half of 2018 was not audited[140]. - The company has not faced any penalties or corrective actions during the reporting period, reflecting compliance with regulatory standards[92]. - The company has disclosed that there are no issues regarding the authenticity and accuracy of its fundraising and usage disclosures[70]. Environmental Responsibility - The company achieved a total COD discharge of 77.58 tons, well below the permitted limit of 256.56 tons, indicating compliance with environmental standards[109]. - The company has established a comprehensive wastewater treatment system with a daily processing capacity of 2300 tons, ensuring compliance with discharge standards[110]. - The company has not reported any environmental pollution incidents, demonstrating effective management of pollution control facilities[111].